Smart Mcell selected as a “next-generation world-class product” by the Ministry of Trade, Industry and Energy.
Recognized for its advanced technology and competitiveness, Miracell has significantly contributed to export growth and national economic development.
It is currently being used in knee osteoarthritis treatment and anti-aging procedures at hospitals and clinics nationwide, including university hospitals.
[Bio Times] Stem cell specialist Miracell (CEO Shin Hyun-soon and Shin Nuri) announced on November 10th that its stem cell extraction system, “SMART M-CELL,” was selected as a next-generation world-class product at the “2023 World-Class Product Certification Ceremony,” held on November 9th at the Grand Ballroom of the Grand Intercontinental Hotel in Seoul.
Hosted by the Ministry of Trade, Industry and Energy (Minister Bang Moon-kyu) and organized by the Korea Trade-Investment Promotion Agency (KOTRA), the ceremony, now in its 23rd year, was attended by approximately 150 representatives from relevant organizations and selected companies. World-class product and manufacturing company certifications were awarded to 73 products and 78 companies.
“Next-Generation World-Class Products” are products with high potential to lead the global market in the future. Miracell’s cell centrifuge, “Smart M-Cell,” has been recognized for its advanced technology and competitiveness, contributing significantly to export growth and national economic development. Miracell was selected as a 2023 Next-Generation World-Class Product and received a certificate from the Minister of Trade, Industry and Energy.
Miracell’s Smart M-Cell is a bio-device capable of extracting large quantities of stem cells. It separates and concentrates stem cells, growth factors, and total cells involved in regeneration from a patient’s blood and bone marrow. Approved by the National Health Technology NET and the FDA, Smart M-Cell boasts a cell viability rate of up to 99% and is used in hospitals and clinics nationwide, including university hospitals, for the treatment of knee osteoarthritis and anti-aging procedures.
Miracell CEO Shin Hyun-soon stated, “Following the direct listing of our bone marrow stem cell injection as a new medical technology for knee osteoarthritis, we are very pleased that the government has recognized Smart Mcell’s technological prowess with this World-Class Product designation. As a leader in regenerative medicine stem cell treatment, we will further expand our exports to the global market and achieve recognition as a world-class product on the global stage.”
Meanwhile, Miracell is exporting its stem cell systems to countries around the world, including Italy, Austria, Greece, and Dubai.
The company also plans to expand its presence in the European market by participating in MEDICA 2023, the world’s largest medical device exhibition, held in Düsseldorf, Germany, from November 13th to 16th.
[Biotimes = Reporter Jeong Min-a] news@biotimes.co.kr
Source: BioTimes (http://www.biotimes.co.kr)